Pfizer Inc. (PFE)
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:02 PM ET · Delayed 15 min
PFE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $156.18B
- P/E (TTM)
- 39.14
- Forward P/E
- 9.28
- EPS (TTM)
- $0.70
- Dividend yield
- 7.85% ($2.15)
- Ex-dividend date
- Nov 6, 2026
- 52-week range
- 23.62 – 31.44
- Day range
- 27.36 – 28.11
- Volume / Avg
- 38.29M / 33.52M
- Beta
- —
- Shares outstanding
- 5.70B
52-week range
PFE stock today
On Nov 20, PFE ended the session at $27.40, shedding $0.14 (0.51%), versus the S&P 500's 3.70% decline. Shares are 12.8% below their 52-week high of $31.44, set on Nov 5, 2026 and 16.0% above the 52-week low of $23.62, in the middle of the past year's range. PFE is up 10.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.4%.
At 39.1x trailing earnings, Pfizer trades above the peer-group median of 20.4x. Its forward P/E of 9.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Pfizer pays an annual dividend of $2.15 per share, a 7.85% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Pfizer
Company profilePfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Albert Bourla D.V.M., Ph.D.
- Headquarters
- New York, NY
- Employees
- 75,000
- Website
- pfizer.com
Financial highlights
Full financialsIn fiscal 2025, Pfizer generated $62.58 billion in revenue, down 1.6% from fiscal 2024, its first annual decline since 2023. Net income was $7.77 billion (-3.2% year over year), for a net margin of 12.4% versus a median of 22.0% in the prior 5 years. Gross margin was 74.3% (up from 71.9%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $62.58B | $63.63B | $59.55B | $101.17B | $81.29B |
| Growth | -1.65% | +6.84% | -41.14% | +24.46% | +95.16% |
| Net income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B |
| EPS (diluted) | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$30.22+10.29%
- Strong buy 1
- Buy 8
- Hold 17
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.56 vs $0.72
- Surprise
- -22.22%
Dividends
Dividend history- Annual dividend
- $2.15
- Dividend yield
- 7.85%
- Last payment
- $0.43
- Ex-dividend date
- Nov 6, 2026
PFE news
All PFE news- Notable healthcare headlines for the week: Health insurers, Pfizer, and J&J in focusSeeking Alpha
- Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?NasdaqJNJ, PFE, LEN.B
- Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?NasdaqNVO, LLY, PFE
- Pfizer: Struggling To Meet Dividend Beyond 2027Seeking Alpha
- Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027Nasdaq
- SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing AgreementGlobeNewswireSRXH, PFE
- Pfizer near-term support and resistance levelsInvesting.com
- Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?NasdaqPFE, LLY, NVO
Pfizer peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs PFE |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs PFE |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs PFE |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs PFE |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs PFE |
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs PFE |
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs PFE |
| TAKTakeda Pharmaceutical Company Limited ADR | 21.77 | +1.68% | $69.55B | vs PFE |
Indexes, lists and sector
Pfizer stock FAQ
What is Pfizer's stock price today?
PFE last traded at $27.40 as of Nov 20, 4:02 PM EST, down 0.51% on the day. Prices are delayed at least 15 minutes.
Does Pfizer pay a dividend?
Yes. Pfizer pays $2.15 per share annually, a 7.85% yield. The most recent dividend of $0.43 had an ex-dividend date of Nov 6, 2026.
What is PFE's P/E ratio?
PFE trades at a trailing P/E ratio of 39.14 and a forward P/E of 9.28, compared with a median of 20.4 for its closest peers.
Is Pfizer in the S&P 500?
Yes. Pfizer (PFE) is a constituent of the S&P 500 index.
Who is Pfizer's CEO?
Dr. Albert Bourla D.V.M., Ph.D. is the chief executive officer of Pfizer Inc., which has about 75,000 employees.
Has PFE ever split its stock?
Yes. The most recent PFE stock split was a 1054-for-1000 split on Nov 17, 2020, one of 6 splits on record.
What is the PFE 52-week high?
The 52-week high for PFE is $31.44 and the 52-week low is $23.62. The stock is currently 12.8% below its high.